PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Avicenna J Med 2015; 05(02): 46-48
DOI: 10.4103/2231-0770.154199
CASE REPORT

Sorafenib induced acral pigmentation: A new entity

Mrinal Gupta
Sudhaa Skin Centre, Jammu, Jammu and Kashmir, India
,
Heena Gupta
Sudhaa Skin Centre, Jammu, Jammu and Kashmir, India
,
Anish Gupta
Sudhaa Skin Centre, Jammu, Jammu and Kashmir, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
 als PDF herunterladen Lizenzen und Reprints
Preview

Abstract

Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepatocellular carcinoma. The commonly reported dermatological adverse effects of Sorafenib include hand-foot syndrome (HFS), alopecia, pruritus, facial and scalp erythema, splinter hemorrhages, keratoacanthomas, squamous cell carcinomas and eruptive melanocytic naevi. We report a case of asymptomatic hyperpigmentation of the palms and soles in a patient receiving Sorafenib therapy for advanced renal cell carcinoma, in the absence of features of classic HFS, which has not been previously reported in the literature.

Keywords

Acral pigmentation - hand foot syndrome - Sorafenib


Publikationsverlauf

Artikel online veröffentlicht:
09. August 2021

© 2015. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Uhlenhake EE, Watson AC, Aronson P. Sorafenib induced eruptive melanocytic lesions. Dermatol Online J 2013;19:18184.
  • 2 Sil A, Das NK. Sorafenib-induced hand-foot syndrome in a patient of renal cell carcinoma. Indian J Pharmacol 2014;46:334-6.
  • 3 Gole P, Madke B, Khopkar U, Kumar P, Noronha V, Yadav M. Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist. Indian Dermatol Online J 2014;5:89-91.
  • 4 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
  • 5 The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring Centre; 2005. Available from: http://www.who-umc.org/graphics/4409.pdf. [Last accessed on 2014 Nov 21].
  • 6 Zekri J, Abdel-Ghany EM. Hyperpigmentation of the tongue, palms and soles: Rare side effect of capecitabine. J Cancer Res Ther 2013;1:226-9.
  • 7 Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol 2001;2:253-62.
  • 8 Lai SE, Kuzel T, Lacouture ME. Hand-foot and stump syndrome to sorafenib. J Clin Oncol 2007;25:341-3.
  • 9 Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: Report of 3 cases and review of the literature. Cutis 2004;73:101-6.
  • 10 Vasudevan B. An unusual case of capecitabine hyperpigmentation: Is hyperpigmentation a part of hand-foot syndrome or a separate entity? Indian J Pharmacol 2010;42:326-8.